

29 April 2026

March 2026 Quarterly Activity Report and Cash Flow Statement

Argent BioPharma Ltd (ASX: RGT) is pleased to update the market for the March 2026 quarter and attaches its Appendix 4C Quarterly Cash Flow report for the period.

Key Operational and Corporate Updates

Argent Completes Acquisition of 48% Interest in CannPal Animal Therapeutics Pty Ltd

During the quarter, the Company completed the acquisition of AusCann Group Holdings Ltd's interest in CannPal Animal Therapeutics Pty Ltd, following shareholder approval. CannPal represents an advanced-stage (Phase 3) veterinary programme targeting seizure management in dogs, with a defined regulatory pathway and potential for near-term commercialisation. The acquisition provides Argent with valuable clinical and safety data, supporting its broader neurological strategy and strengthening the positioning of its CannEpil® programme.

Strategically, the transaction expands the Company's portfolio, adding a late-stage asset with standalone commercial potential while enhancing its clinical and regulatory dataset. The Neuvis® option introduces additional flexibility, offering potential applications across the Company's pipeline to improve formulation performance, lifecycle management, and intellectual property positioning.

Overall, the acquisition marks a key milestone in advancing Argent's neuro-immune strategy, broadening its asset base across both human and veterinary applications, and aligning its portfolio with the scale and requirements of a potential U.S. national exchange listing.

Largest Commercial Shipment of CannEpil® Arrives in Ireland

Argent BioPharma completed its largest-ever commercial shipment of CannEpil®, with 1,000 units delivered to Ireland. The shipment, distributed via the Company's Irish commercial partner Georgelle Pharma and European logistics partner Versa Pharmaceuticals d.o.o., represents an approximate reimbursed retail value of ~A\$783,000.

The milestone follows the successful manufacture of CannEpil® under EU-GMP standards through the Company's OEM partner, demonstrating Argent's capability to deliver scaled commercial supply within regulated pharmaceutical frameworks. CannEpil® is a pharmaceutical-grade cannabinoid formulation developed for the management of seizures associated with refractory epilepsy and is currently supplied under regulated medical pathways.



In Ireland, CannEpi[®] is fully reimbursed under the national health insurance scheme, supporting patient access and reinforcing the product's commercial viability within a regulated European market. While revenue recognition will depend on dispensing volumes and reimbursement mechanics, the shipment represents a key step in advancing commercialisation.

Overall, the delivery strengthens Argent's European distribution infrastructure, expands reimbursed patient access, and marks a significant commercial milestone for CannEpi[®] as a core component of the Company's neurological portfolio.

U.S. Provisional Patent for Novel NanoBodies Platform Targeting Septic Shock and Systemic Inflammation

Argent BioPharma also progressed its internal NanoBodies research programme, with a provisional patent application filed with the United States Patent and Trademark Office (Application No. 63/979,136). The filing secures priority protection for the platform's peptide targets and associated nanobody constructs, establishing a 12-month period for further development and validation.

The NanoBodies platform is focused on vascular and peptide-mediated signalling mechanisms implicated in septic shock and systemic inflammatory disorders, expanding the Company's immune-modulatory portfolio beyond cytokine regulation into upstream pathways involved in inflammatory progression.

Planned preclinical studies utilising a cecal ligation and perforation (CLP) model will assess vascular stability, immune modulation, and key inflammatory biomarkers. The programme complements Argent's existing pipeline, including CimetrA[®], and further reinforces its integrated neuro-immune strategy.

Overall, the initiative broadens the scientific depth of the Company's portfolio and strengthens its U.S.-focused intellectual property position across immune and inflammatory indications.


Corporate

Operating outflows totalled A\$788k for the period, with A\$151k related to staff costs and A\$67k associated with research and development activities. At the end of the period, the Company had a closing cash balance of A\$736k.

In accordance with ASX Listing Rule 4.7C.3 the Company advises that during the March 2026 quarter, payments to related parties totalled A\$77k, which consisted of fees paid to executive and non-executive directors of the Company.

Science meets protocol. Precision meets care.

—Ends—



Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com



Authorised for release by the board of directors, for further information please contact:

Argent BioPharma

Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma

Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its lead assets, *CannEpi*[®] and *Cimetra*[®], target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The company's proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection. With integrated EU-GMP manufacturing, clinical-stage programs, and a unified Neuro-Immune Modulatory platform, Argent BioPharma is advancing a high-impact pipeline that excludes oncology and focuses on urgent unmet needs in CNS and systemic inflammation

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma



Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Argent BioPharma Limited

ABN

30 116 800 269

Quarter ended ("current quarter")


31 March 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	63	198
1.2	Payments for		
	(a) research and development	(67)	(227)
	(b) product manufacturing and operating costs		
	i) cost of sales / inventory	-	(75)
	ii) operating costs	(6)	(137)
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(151)	(1,092)
	(f) administration and corporate costs (including product registrations)	(620)	(2,128)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (GST/VAT refund)	(7)	(32)
1.9	Net cash from / (used in) operating activities	(788)	(3,493)



Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.	Cash flows from investing activities		
2.1	Payments to acquire:	-	-
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	(2)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	1
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (cash acquired through assets acquisition)	-	-
2.6	Net cash from / (used in) investing activities	-	(1)

3.	Cash flows from financing activities	Current quarter \$A'000	Year to date (9 months) \$SA'000
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	272
3.2	Proceeds from issue of convertible debt securities	-	3,000
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(5)	(63)
3.5	Proceeds from borrowings	-	-





Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (loan entity which where control was gained after quarter-end)	-	-
3.10	Net cash from / (used in) financing activities	(5)	3,209

4.	Net increase / (decrease) in cash and cash equivalents for the period	Current quarter \$A'000	Year to date (9 months) \$A'000
4.1	Cash and cash equivalents at beginning of period	1,529	1,024
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(788)	(3,493)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(1)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(5)	3,209
4.5	Effect of movement in exchange rates on cash held	-	(3)
4.6	Cash and cash equivalents at end of quarter	736	736





5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	736	1,529
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	736	1,529

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	77
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.		

The payments in 6.1 are payments to directors of the company for their service during the quarter.






7.	Financing facilities available <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	25,600	9,948
7.4	Total financing facilities	25,600	9,948
7.5	Unused financing facilities available at quarter end	-	15,652
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
<p>\$14.6M Convertible note facility with Mercer Street Opportunity Fund LLC. Refer to ASX announcement on 29 July 2022 for further information.</p> <p>\$11M Convertible note facility with C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC. Refer to ASX announcement on 17 November 2025 for further information.</p>			

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (Item 1.9)	(788)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	736
8.3	Unused finance facilities available at quarter end (Item 7.5)	15,652
8.4	Total available funding (Item 8.2 + Item 8.3)	16,388
8.5	Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	20.8
<p><i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i></p>		
8.6	If Item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
	2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	





	<p>3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?</p> <p>Answer: N/A</p>
<p><i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i></p>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

29 April 2026

Date:

[lodge electronically without signature]

Authorised by:

Roby Zomer – Chairman

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the *[name of board committee – eg Audit and Risk Committee]*”. If it has been authorised for release to the market by a disclosure committee, you can insert here: “By the Disclosure Committee”.
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council’s *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

